ACHL

Achilles Therapeutics
ACHL

$0.86
2.8%
 

About: Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Employees: 215

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

60% more funds holding

Funds holding: 20 [Q4 2023] → 32 (+12) [Q1 2024]

52% more capital invested

Capital invested by funds: $19.4M [Q4 2023] → $29.4M (+$10M) [Q1 2024]

4.22% more ownership

Funds ownership: 53.21% [Q4 2023] → 57.43% (+4.22%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$2
132%
upside
Avg. target
$4
363%
upside
High target
$6
595%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Chardan Capital
Geulah Livshits
595%upside
$6
Buy
Maintained
5 Apr 2024
Piper Sandler
Joseph Catanzaro
132%upside
$2
Neutral
Downgraded
5 Apr 2024

Financial journalist opinion